Mesenchymal stem cell therapy for degenerative inflammatory disorders
Standard
Mesenchymal stem cell therapy for degenerative inflammatory disorders. / Müller, Ingo; Lymperi, Stefania; Dazzi, Francesco.
in: CURR OPIN ORGAN TRAN, Jahrgang 13, Nr. 6, 12.2008, S. 639-44.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mesenchymal stem cell therapy for degenerative inflammatory disorders
AU - Müller, Ingo
AU - Lymperi, Stefania
AU - Dazzi, Francesco
PY - 2008/12
Y1 - 2008/12
N2 - PURPOSE OF REVIEW: In recent years, the multilineage differentiation potential of mesenchymal stem cells (MSCs) in combination with their highly immunosuppressive properties has been extensively studied and exploited for a number of diseases. Here, we review the recent findings supporting the therapeutic use in the clinic and the mechanisms by which MSCs may deliver such an effect.RECENT FINDINGS: The results of using MSCs for tissue repair have been controversial in both humans and animal models. Despite the successful manipulation in vitro, MSCs fail to consistently differentiate at the site of lesion. However, there is evidence that paracrine mechanisms eventually drive tissue repair. Conversely, MSCs have been used with great success in the clinical treatment of severe graft-versus-host disease, and animal models suggest that they may be equally effective in a variety of autoimmune diseases. The therapeutic efficacy of MSCs depends on a licensing stage provided by the inflammatory microenvironment, which makes MSCs tolerogenic.SUMMARY: Although encouraging, the therapeutic potentials of MSCs warrant further studies. In particular, the optimization of their in-vitro expansion and the characterization of disease-specific environment in which MSCs exert their function will provide crucial information to maximize their beneficial effects.
AB - PURPOSE OF REVIEW: In recent years, the multilineage differentiation potential of mesenchymal stem cells (MSCs) in combination with their highly immunosuppressive properties has been extensively studied and exploited for a number of diseases. Here, we review the recent findings supporting the therapeutic use in the clinic and the mechanisms by which MSCs may deliver such an effect.RECENT FINDINGS: The results of using MSCs for tissue repair have been controversial in both humans and animal models. Despite the successful manipulation in vitro, MSCs fail to consistently differentiate at the site of lesion. However, there is evidence that paracrine mechanisms eventually drive tissue repair. Conversely, MSCs have been used with great success in the clinical treatment of severe graft-versus-host disease, and animal models suggest that they may be equally effective in a variety of autoimmune diseases. The therapeutic efficacy of MSCs depends on a licensing stage provided by the inflammatory microenvironment, which makes MSCs tolerogenic.SUMMARY: Although encouraging, the therapeutic potentials of MSCs warrant further studies. In particular, the optimization of their in-vitro expansion and the characterization of disease-specific environment in which MSCs exert their function will provide crucial information to maximize their beneficial effects.
KW - Animals
KW - Apoptosis
KW - Autoimmune Diseases
KW - Cell Differentiation
KW - Cell Lineage
KW - Cell Proliferation
KW - Humans
KW - Immune Tolerance
KW - Inflammation
KW - Inflammation Mediators
KW - Mesenchymal Stem Cell Transplantation
KW - Mesenchymal Stromal Cells
KW - Transplantation, Autologous
KW - Transplantation, Homologous
U2 - 10.1097/MOT.0b013e328317a462
DO - 10.1097/MOT.0b013e328317a462
M3 - SCORING: Journal article
C2 - 19060556
VL - 13
SP - 639
EP - 644
JO - CURR OPIN ORGAN TRAN
JF - CURR OPIN ORGAN TRAN
SN - 1087-2418
IS - 6
ER -